Point-Of-Care International Normalized Ratio (INR) Testing Market Outlook: Strong Revenue and CAGR Growth Forecast Through 2030

 What Are the Key Growth Indicators and Market Expansion Estimates for the Point-Of-Care International Normalized Ratio (INR) Testing Market Through 2030?

 The point-of-care inr testing market size has grown rapidly in recent years. It will grow from $1.58 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, growing use of anticoagulant therapy, rising incidence of atrial fibrillation, expansion of outpatient and homecare settings, increasing need for rapid coagulation testing.
 
 The point-of-care inr testing market size is expected to see rapid growth in the next few years. It will grow to $2.56 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for home-based monitoring, growing geriatric population on long-term anticoagulation, rising focus on personalized anticoagulation management, expansion of decentralized healthcare models, increasing adoption in primary care clinics. Major trends in the forecast period include technological advancements in portable coagulation analyzers, innovations in biosensor and microfluidic technologies, developments in wireless connectivity and data integration, research and development in high-accuracy test strips, advancements in smartphone-enabled inr testing.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=30703&type=smp
 
 What Are the Leading Drivers Behind the Growth of the Point-Of-Care International Normalized Ratio (INR) Testing Market?
 The rising prevalence of cardiovascular diseases is expected to propel the growth of the point-of-care International Normalized Ratio (INR) testing market going forward. Cardiovascular diseases are conditions that affect the heart and blood vessels, including heart attacks, strokes, and hypertension. Cardiovascular diseases are increasing due to unhealthy lifestyles such as poor diet, lack of exercise, and smoking. Point-of-care International Normalized Ratio (INR) testing aids in cardiovascular disease diagnosis by enabling rapid assessment of blood coagulation status at the bedside or clinic. It improves clinical decision-making by supporting timely detection of clotting abnormalities and guiding anticoagulation therapy. For instance, in October 2024, according to the Centers for Disease Control, a US-based government agency, in 2023, approximately 919,032 people died from cardiovascular disease, accounting for 1 in every 3 deaths. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of the point-of-care International Normalized Ratio (INR) testing market.
 
 What Are the Primary Market Segments in the Point-Of-Care International Normalized Ratio (INR) Testing Market?
 The point-of-care international normalized ratio (inr) testing market covered in this report is segmented — 
 
 1) By Product Type: Devices, Consumables, Software
 2) By Technology: Electrochemical, Optical, Others
 3) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Or E-Commerce, Others
 4) By Application: Hospitals, Clinics, Home Care, Diagnostic Centers, Others
 5) By End-User: Healthcare Professionals, Patients
 
 Subsegments:
 1) By Devices: Portable Testing Devices, Handheld Testing Devices, Desktop Testing Devices
 2) By Consumables: Test Strips, Cartridges, Control Solutions
 3) By Software: Data Management Software, Remote Monitoring Software, Analytical Software
 
 What New Market Trends Are Emerging in the Point-Of-Care International Normalized Ratio (INR) Testing Market?
 Major companies operating in the point-of-care International Normalized Ratio (INR) testing market are focusing on developing advanced products, such as patient self-monitoring coagulation analyzers, to expand decentralized testing and shift recurring demand toward lower-cost consumables. Patient self-monitoring coagulation analyzers are portable devices that enable patients to perform PT/INR testing at home using a small capillary blood sample, supporting frequent monitoring while reducing dependence on clinical visits. For instance, in March 2024, Universal Biosensors, an Australia-based medical device company, launched the Xprecia Prime 4U Coagulation Analyzer for patient self-monitoring. This self-monitoring coagulation analyzer fits in the palm of the hand, delivers rapid PT/INR results from a single drop of capillary blood, and uses an electrochemical strip format that supports regulatory approvals, including 510(k) clearance and CLIA waiver for the U.S. market. This launch represents an important advancement in INR testing by enabling broader access to home monitoring, increasing test frequency, and improving cost efficiency through higher consumable utilization while maintaining clinical accuracy.
 
 Who Are the Top Industry Players Driving the Point-Of-Care International Normalized Ratio (INR) Testing Market Growth?
 Major companies operating in the point-of-care international normalized ratio (inr) testing market are Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company, Hoffmann-La Roche Ltd., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Werfen S.A., HORIBA Ltd., Microvisk Ltd., Randox Laboratories Ltd., Nova Biomedical Corporation, Agappe Diagnostics Ltd., Visby Medical Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, HemoSonics LLC, Human Diagnostics Worldwide GmbH, CoaguSense Inc. 
 
 Get the detailed point-of-care international normalized ratio (inr) testing market report today
 https://www.thebusinessresearchcompany.com/report/point-of-care-international-normalized-ratio-inr-testing-market-report
 
 Which Regional Markets Offer the Most Promising Growth Opportunities for the Point-Of-Care International Normalized Ratio (INR) Testing Market?
 North America was the largest region in the Point-of-Care INR Testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point-of-care international normalized ratio (inr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company